Pi­lot crash crush­es lit­tle Galectin’s share price af­ter NASH study fails

The next time a biotech team de­cides to run a quick proof-of-con­cept study to back up their clin­i­cal quest on a drug de­signed to fight a big-mar­ket dis­ease, they might want to care­ful­ly con­sid­er what can go wrong.

Take Galectin $GALT, for ex­am­ple.

De­vel­op­ing a new NASH con­tender, a hot field for drug de­vel­op­ers these days, the small Nor­cross, GA-based biotech de­cid­ed to re­cruit 30 pa­tients for a short “pi­lot” tri­al to run a few months, with a bio­mark­er on liv­er fi­bro­sis in fo­cus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER